Beijing Tong Ren Tang Chinese Medicine Company Limited Stock

Equities

3613

HK0000145638

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:16 2024-04-24 am EDT 5-day change 1st Jan Change
9.26 HKD +1.76% Intraday chart for Beijing Tong Ren Tang Chinese Medicine Company Limited +2.55% -23.72%
Sales 2024 * 1.74B 222M Sales 2025 * 1.99B 254M Capitalization 7.62B 973M
Net income 2024 * 652M 83.24M Net income 2025 * 758M 96.78M EV / Sales 2024 * 2.76 x
Net cash position 2024 * 2.83B 362M Net cash position 2025 * 2.63B 336M EV / Sales 2025 * 2.51 x
P/E ratio 2024 *
11.7 x
P/E ratio 2025 *
9.07 x
Employees 798
Yield 2024 *
4.4%
Yield 2025 *
5.11%
Free-Float 28.23%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Tong Ren Tang Chinese Medicine CEO Steps Down; Acting CEO Appointed MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes CI
Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Yu Jin as an Executive Director and Member of the Competition Executive Committee CI
Beijing Tong Ren Tang Chinese Medicine's Profit Falls on Lower Revenue MT
Beijing Tong Ren Tang Chinese Medicine Signs E-Commerce Framework Agreement MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on June 17,2024 CI
Beijing Tong Ren Tang Chinese Medicine Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Tong Ren Tang Flags Up to 22% Profit Drop in 2023 MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023 CI
Beijing Tong Ren Tang Appoints Chairman MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative CI
Beijing Tong Ren Tang to Vote Dec. 27 on Renewal of Distributorship Contracts MT
Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes New Exclusive Distributorship Framework Agreements CI
Chinese listed firms used endangered animal parts as ingredients -report RE
Three listed Chinese firms used endangered animal parts as ingredients- report RE
More news
1 day+1.76%
1 week+2.55%
Current month+3.46%
1 month+1.42%
3 months-17.62%
6 months-21.12%
Current year-23.72%
More quotes
1 week
8.95
Extreme 8.95
9.26
1 month
8.85
Extreme 8.85
9.31
Current year
8.75
Extreme 8.75
12.44
1 year
8.75
Extreme 8.75
16.66
3 years
8.51
Extreme 8.51
16.66
5 years
7.75
Extreme 7.75
16.66
10 years
7.55
Extreme 7.55
17.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 -
Director of Finance/CFO 48 12-09-30
Chief Tech/Sci/R&D Officer 54 07-12-31
Members of the board TitleAgeSince
Director/Board Member 52 13-04-14
Chairman 59 Dec. 12
Director/Board Member 76 17-09-11
More insiders
Date Price Change Volume
24-04-24 9.26 +1.76% 1 509 000
24-04-23 9.1 +0.22% 782,109
24-04-22 9.08 +0.55% 542,000
24-04-19 9.03 0.00% 502,000
24-04-18 9.03 0.00% 451,000

Delayed Quote Hong Kong S.E., April 24, 2024 at 04:08 am EDT

More quotes
Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. It is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.1 HKD
Average target price
13.92 HKD
Spread / Average Target
+53.02%
Consensus

Annual profits - Rate of surprise